Sichenzia Ross Friedman Ference LLP Advises Citius Pharmaceuticals, LLC on a Reverse Merger and $2.04 Million Pipe Financing
September 18, 2014 (GLOBE NEWSWIRE) – New York – based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Citius Pharmaceuticals, LLC (OTCQB: CTXR) – a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets- in connection with a Share Exchange and Reorganization Agreement between Citius Pharmaceuticals, LLC, Citius Pharmaceuticals, Inc. (formerly known as Trail One. Inc.) and the beneficial holders of the membership interests of Citius.
Pursuant to the “Exchange Agreement”, Citius Pharmaceuticals, Inc. issued common stock to the holders of the membership interests of Citius representing approximately 72.0% of the outstanding shares of common stock.
In connection with the “Exchange Agreement”, Sichenzia Ross advised Citius on a private offering whereby Citius sold 3,4000,067 Units for a purchase price of $0.60 per Unit for a total value of $2.04 million. Each Unit sold consisted of one share of common stock and a five-year warrant. The Sichenzia Ross Friedman Ference LLP team was led by Partners Gregory Sichenzia and Arthur S. Marcus.
- Sichenzia Ross Ference LLP Represents ThinkEquity LLC in $17.25 Million Initial Public Offering of Common Stock of Forza X1, Inc. - August 17, 2022
- Sichenzia Ross Ference LLP Joins Splash Beverage Group, Inc. in Ringing Opening Bell at NYSE - July 29, 2022
- Sichenzia Ross Ference LLP Represents Roth Capital Partners in Public Offering of Common Stock of Crown Electrokinetics Corp. - July 26, 2022